Order online in 2 minutes, visit a local lab same day, and get results in 1-3 days. No doctor's order needed.
GLP-1 receptor agonists (like semaglutide and tirzepatide) do not directly cause thyroid issues in most people, but they carry a specific warning for a rare type of thyroid tumor called medullary thyroid carcinoma (MTC). Today, this remains a black-box warning from the FDA, based on animal studies. For the vast majority of patients without a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2), GLP-1 therapy is considered safe for the thyroid. However, understanding the nuanced relationship between GLP-1 and thyroid health is essential for informed decision-making.
GLP-1 receptors are present in the thyroid gland, particularly on C-cells that produce calcitonin. In rodent studies, high doses of GLP-1 drugs stimulated C-cell hyperplasia and MTC. Human studies, however, have not shown a significant increase in MTC incidence among users. A recent meta-analysis of 18 trials found no statistically significant rise in calcitonin levels or thyroid cancer in humans over 5 years of use. Still, regulatory agencies advise against use in patients with MEN-2 or family history of MTC.
For patients without risk factors, routine thyroid monitoring is not mandatory but can be prudent. If you experience a neck lump, difficulty swallowing, or hoarseness while on GLP-1 therapy, your doctor may order a thyroid ultrasound and calcitonin blood test. Today, guidelines from the Endocrine Society suggest baseline calcitonin measurement only for those with suspicious symptoms or family history.
| Test | When to Consider | Normal Range |
|---|---|---|
| Calcitonin (blood) | Baseline if family risk, or if neck symptoms appear | < 10 pg/mL (men), < 5 pg/mL (women) |
| Thyroid Ultrasound | If calcitonin elevated or palpable nodule | No suspicious nodules |
| TSH (thyroid stimulating hormone) | Routine thyroid health check (not GLP-1-specific) | 0.4–4.0 mIU/L |
Some patients report mild thyroid enlargement or transient changes in thyroid hormone levels, but these are rare and usually resolve without intervention. GLP-1 drugs do not cause hypothyroidism or hyperthyroidism directly. However, weight loss itself can alter thyroid hormone metabolism, so periodic monitoring of TSH may be wise if you lose significant weight.
Most thyroid nodules are benign. MTC is rare (1-2% of thyroid cancers). The black-box warning exists because MTC can be aggressive, and animal data suggested a link. Human data remain reassuring: a FDA review of post-marketing surveillance found no confirmed cases of MTC attributable to GLP-1 use in patients without pre-existing risk.
If you are on or considering GLP-1 therapy, a simple blood test can provide peace of mind. mylabpanel offers a comprehensive Thyroid Panel that includes TSH, free T4, free T3, and thyroid antibodies. For those with concerns about MTC, a Calcitonin Blood Test is available. These tests help establish a baseline before starting GLP-1 and can be repeated if symptoms arise.
Take control of your thyroid health today. Order the mylabpanel Thyroid Panel or Calcitonin Test to ensure your thyroid is functioning optimally while on GLP-1 therapy. Knowledge is your best defense.